Overview

Corporate ProfileNantHealth is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth‘s unique systems-based approach to personalized healthcare integrates novel diagnostics with large-scale, biometric and phenotypic data to track patient outcomes and deliver precision medicine. In addition, NantHealth’s adaptive learning system, CLINICS, continuously improves decision-making and further optimizes our clinical pathways and decision algorithms over time.

Stock Quote

(Common Stock)  
Exchange
Volume
Today's Open
Previous Close
Data as of

Copyright West LLC. Minimum 15 minutes delayed.

Stock Chart

Recent News
December 11, 2019
NantHealth Presents Research Demonstrating Real World Evidence of Simultaneous Presentation and Publication of Oncology Data at the 2019 San Antonio Breast Cancer Symposium
Eviti Connect study showed an increase in clinical uptake of practice-changing data SAN ANTONIO --(BUSINESS WIRE)--Dec. 11, 2019-- NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced new breast cancer research findings presented during
Read More >
November 12, 2019
NantHealth Announces FDA Marketing Authorization of Omics Core℠: The Nation’s First Tumor-Normal Mutation Profiling of Overall Tumor Mutational Burden from Whole Exome Sequencing in Solid Tumors
Landmark FDA clearance of whole exome sequencing in vitro diagnostic (IVD) test reporting overall tumor mutation burden (TMB) by sequencing 19,396 protein-coding genes (whole exome) targeting 39 million base pairs (39 Mb) of the human genome from patient tumor and matched normal sample
Read More >
November 7, 2019
NantHealth Reports 2019 Third-Quarter Financial Results
  Q3 Financial Highlights: Total revenue was $22.4 million SaaS revenue was $18.3 million , up 15% from Q3 2018 Total gross margin increased to 63% from 50% in Q3 2018 Company was cash flow positive, with cash growing by $2.3 million from Q2 2019 to $9.3 million at Q3 2019 Software and Service
Read More >

Upcoming Events

There are currently no events to display.